CoChat
Sign Up
Cited by 234Blood Pressure and Hypertension StudiesHormonal Regulation and HypertensionRenin-Angiotensin System Studies

Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension

de Souza, Fabio, Muxfeldt, Elizabeth, Fiszman, Roberto, Salles, Gil·2010·Hypertension
DOI 10.1161/hypertensionaha.109.140988
Open this paper in CoChat — free account

Abstract

The role of spironolactone in resistant hypertension management is unclear. The aim of this prospective trial was to evaluate the antihypertensive effect of spironolactone in patients with true resistant hypertension diagnosed by ambulatory blood pressure monitoring. A total of 175 patients had clinical and complementary exams obtained at baseline and received spironolactone in doses of 25 to 100 mg/d. A second ambulatory blood pressure monitoring was performed after a median interval of 7 months. Paired Student t test was used to assess differences in blood pressure before and during spironolactone administration, and multivariate analysis adjusted for age, sex, and number of antihypertensive drugs to assess the predictors of blood pressure fall. There were mean reductions of 16 and 9 mm Hg, respectively, in 24-hour systolic and diastolic blood pressures (95% CIs: 13 to 18 and 7 to 10 mm Hg; P <0.001). Office systolic blood pressure and diastolic blood pressure also decreased (14 and 7 mm Hg). Controlled ambulatory blood pressure was reached in 48% of patients. Factors associated with better response were higher waist circumference, lower aortic pulse wave velocity, and lower serum potassium. No association with plasma aldosterone or aldosterone:renin ratio was found. Adverse effects were observed in 13 patients (7.4%). A third ambulatory blood pressure monitoring performed in 78 patients after a median of 15 months confirmed the persistence of the spironolactone effect. In conclusion, spironolactone administration to true resistant hypertensive patients is safe and effective in decreasing blood pressure, especially in those with abdominal obesity and lower arterial stiffness. Its addition to an antihypertensive regimen as the fourth or fifth drug is recommended.

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.109.140988

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with obesity and treatment-resistant hypertension treated with spironolactone, reductions in blood pressure did not correlate with plasma aldosterone concentration.

    “Moreover, in patients with obesity and treatment-resistant hypertension who were treated with spironolactone, the resulting reductions in BP did not correlate with plasma aldosterone concentration73,74.”

    From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [74]

  • Administration of MR antagonists provides significant antihypertensive benefit in treatment resistant obese patients, although there was no correlation between plasma aldosterone levels and BP responses to MR blockade.

    “Administration of MR antagonists provides significant antihypertensive benefit in treatment resistant obese patients, although there was no correlation between plasma aldosterone levels and BP responses to MR blockade52,53.”

    From Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms (2015) · cites this paper as [52]

  • In patients who are not overtly volume overloaded but who have evidence of low renin status or salt sensitivity of BP, mineralocorticoid receptor antagonists (spironolactone or eplerenone) are more successful than α- or β-blockers.

    “In patients who are not overtly volume overloaded but who have evidence of low renin status or salt sensitivity of BP, mineralocorticoid receptor antagonists (spironolactone or eplerenone) are more successful than α- or β-blockers.373,377”

    From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [377]

  • Recent reports document the efficacy of mineralocorticoid receptor blockade to improve BP in patients with resistant hypertension.

    “Recent reports document the efficacy of mineralocorticoid receptor blockade (Figure 3, step 3, and Table 4) to improve BP in patients with RH.373–377”

    From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [377]

  • Mineralocorticoid receptor blockade has beneficial effects on blood pressure in obese subjects even in those displaying resistant hypertension.

    “These observations are also consistent with the beneficial effects of mineralocorticoid receptor blockade on blood pressure in obese subjects even in those displaying resistant hypertension (55).”

    From Obesity-Associated Hypertension: Recent Progress in Deciphering the Pathogenesis (2014) · cites this paper as [55]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
de Souza, F., Muxfeldt, E., Fiszman, R., & Salles, G.
Affiliations
  • From the Hypertension Program, University Hospital Clementino Fraga Filho, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Universidade Federal do Rio de Janeiro (BR)
ORCID
Venue
Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-01
Volume
55
Issue
1
Pages
147-152
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
DOI
10.1161/hypertensionaha.109.140988
OpenAlex
W2135100154
Cited by
234
References
32
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 10 · 2019: 8 · 2018: 11 · 2017: 13 · 2016: 18 · 2015: 19 · 2014: 26 · 2013: 31 · 2012: 26
FWCI
15.52
Type
journal article
Language
en
Open access
closed
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
spironolactone, resistant hypertension, antihypertensive therapy, ambulatory blood pressure monitoring, blood pressure reduction, predictors of treatment response, waist circumference, abdominal obesity, arterial stiffness, pulse wave velocity, serum potassium, aldosterone, adverse effects
MeSH terms
Blood Pressure, Breast Diseases, Diuretics, Follow-Up Studies, Gynecomastia, Humans, Hypertension, Prospective Studies, Spironolactone, Multivariate Analysis, Linear Models, Treatment Outcome, Blood Pressure Monitoring, Ambulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review